Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Porton, Aojin Partner to Advance XDC Conjugate Drugs for Dual IND Filings in China & the U.S. | Contract Pharma
Breaking News, Collaborations & Alliances

Porton, Aojin Partner to Advance XDC Conjugate Drugs for Dual IND Filings in China & the U.S.

Aim to promote the vigorous development of global XDC conjugate drugs, enabling the public's early access to good medicines.

Porton Pharma Solutions Ltd., an end-to-end CDMO, has teamed up with Aojin Life Sciences (Yixing) Co., Ltd. to offer extensive CDMO services for Aojin in the CMC pharmaceutical research and GMP production of XDC conjugate drugs, focusing on dual IND filings in both China and the United States.
 
With nearly two decades of experience in providing integrated CDMO services, Porton has formed a multidisciplinary project team that connects drug substance and drug product technologies, blending expertise in both small and large molecules. This partnership ushers in a detailed and strategic collaboration between Porton and Aojin in the XDC conjugate drug field. Together, the companies are committed to advancing the global development of XDC conjugate drugs, ensuring early access to high-quality medicines for the public.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters